Join
Live feed
·
PRReleasevia Quantisnow
Climb Bio Inc. logo

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

ByQuantisnow·Wall Street's wire, on your screen.
CLYM· Climb Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLYM (Climb Bio Inc.) and more on Quantisnow.